sorafenib: the current standard of care
Published 9 years ago • 3.8K plays • Length 6:50Download video MP4
Download video MP3
Similar videos
-
6:02
hcc: considerations in first-line use of sorafenib
-
5:40
sorafenib initiation after tace in hcc
-
8:10
dosing strategies with sorafenib in hcc
-
4:40
decision trial: support for sorafenib
-
6:29
sorafenib side effect management in thyroid cancer
-
4:35
hcc treatment: sorafenib tace
-
9:47
sorafenib in advanced dtc
-
5:16
practical views on sorafenib
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
6:51
hcc: use of lenvatinib and sorafenib
-
5:28
assessing response to sorafenib
-
1:21
dr. abou-alfa on sorafenib plus doxorubicin in patients with hcc
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
1:15
dr. vaishampayan on the safety of tivozanib versus sorafenib in rcc
-
3:18
rationale and study design of a phase iii study of sorafenib and sbrt for hepatocellular carcinoma
-
1:11
regorafenib vs sorafenib in the treatment of liver cancer
-
6:53
sequencing in dtc: lenvatinib and sorafenib
-
4:33
results from a phase iii study of sorafenib and sbrt for hepatocellular carcinoma
-
3:05
imbrave150: updated data on atezo plus bev versus sorafenib in hcc